Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis-Reference-Cited by-同舟云学术

Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis

Published:1991-10 Issue:4 Volume:16 Page:299-303
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:European Journal of Drug Metabolism and Pharmacokinetics

Author:

Tharasse-Bloch C.,Chabenat C.,Boucly P.,Marchand J.,Elkharrat D.,Boucly-Goester C.,Gajdos P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/BF03189975.pdf

Reference17 articles.

1. Desmedt J.E. (1957): Premiers résultats thérapeutiques avec la Mytélase (Mysuran, WIN 8077) dans la myasthénie. Acta Neurol. Psych. Belg., 57, 94–103.

2. Grob D. (1958): Myasthenia gravis. J. Chron. Dis., 8, 536–566.

3. Szobor A. (1969): On the treatment of myasthenia gravis. Acta Med. Acad Sci Hung., 26, 103–119.

4. Tharasse-Bloch C., Chabenat C., Boucly P., Marchand J. (1987): Determination of ambenonium chloride in serum by reversed-phase ion-pair liquid chromatography. J. Chromatogr., 421, 407–411.

5. Tharasse-Bloch C., Chabenat C., Boucly P., Marchand J. (1989): Pharmacokinetics of ambenonium chloride in dogs after intravenous and oral administration. Arzneimittelforschung., 39, 257–258.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-547, a 6-methyluracil derivative with long-lasting binding and rebinding on acetylcholinesterase: Pharmacokinetic and pharmacodynamic studies;Neuropharmacology;2018-03

2. Small Quaternary Inhibitors K298 and K524: Cholinesterases Inhibition, Absorption, Brain Distribution, and Toxicity;Neurotoxicity Research;2015-12-08

3. Pharmacodynamic analysis of contractile potentiation by cholinesterase inhibitors in rats;Journal of Pharmacokinetics and Biopharmaceutics;1996-08